drugset / Trial / NCT00913458

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

NCT00913458

Phase 4 Completed 306 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.

Timeline

Start
2009-09
Primary completion
2012-06
Completion
2012-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg
Subject Etanercept Protein / enzyme biologic 50 mg

Indications